A solid preparation comprising (A) and (B): (A) a granulated substance which comprises (i) a poorly soluble drug having an acidic group in the molecule, (ii) an alkaline agent, (iii) a surfactant, and this granulated substance does not substantially contain a disintegrator, (B) a disintegrator existing only in the external of the granulated substance; wherein the alkaline agent is one or more compounds containing in the molecules one or more selected from the group consisting of magnesium and aluminum, wherein the disintegrator is one or more selected from the group consisting of (i) cellulosic derivative(s), which are selected from the group consisting of low substituted hydroxypropyl cellulose, carmellose, carmellose calcium and croscarmellose sodium, (ii) polyvinyl pyrrolidone derivative(s), which is crospovidone and (iii) starch derivative(s), which is carboxymethyl starch sodium, and wherein the poorly soluble drug is an optically active compound represented by Formula (I): wherein, R1 is halogen atom or C1 - C3 alkyloxy; R2 is C1 - C8 alkyl; R3 is C1 - C8 alkyl; R4 and R5 are each independently fluorine atom or chlorine atom; R6 is C1 - C3 alkyl or C1 - C3 alkyloxy; and carbon atom with "*" attached to it is an asymmetric carbon, its pharmaceutically acceptable salt, or solvate thereof. (A) a granulated substance which comprises (i) a poorly soluble drug having an acidic group in the molecule, (ii) an alkaline agent, (iii) a surfactant, and this granulated substance does not substantially contain a disintegrator, (i) a poorly soluble drug having an acidic group in the molecule, (ii) an alkaline agent, (iii) a surfactant, and this granulated substance does not substantially contain a disintegrator, (ii) an alkaline agent, (iii) a surfactant, (B) a disintegrator existing only in the external of the granulated substance; wherein the alkaline agent is one or more compounds containing in the molecules one or more selected from the group consisting of magnesium and aluminum, wherein the disintegrator is one or more selected from the group consisting of (i) cellulosic derivative(s), which are selected from the group consisting of low substituted hydroxypropyl cellulose, carmellose, carmellose calcium and croscarmellose sodium, (ii) polyvinyl pyrrolidone derivative(s), which is crospovidone and (iii) starch derivative(s), which is carboxymethyl starch sodium, and wherein the poorly soluble drug is an optically active compound represented by Formula (I): wherein, R1 is halogen atom or C1 - C3 alkyloxy; R2 is C1 - C8 alkyl; R3 is C1 - C8 alkyl; R4 and R5 are each independently fluorine atom or chlorine atom; R6 is C1 - C3 alkyl or C1 - C3 alkyloxy; and carbon atom with "*" attached to it is an asymmetric carbon, its pharmaceutically acceptable salt, or solvate thereof. (i) cellulosic derivative(s), which are selected from the group consisting of low substituted hydroxypropyl cellulose, carmellose, carmellose calcium and croscarmellose sodium, (ii) polyvinyl pyrrolidone derivative(s), which is crospovidone and (iii) starch derivative(s), which is carboxymethyl starch sodium, wherein the poorly soluble drug is an optically active compound represented by Formula (I): wherein, R1 is halogen atom or C1 - C3 alkyloxy; R2 is C1 - C8 alkyl; R3 is C1 - C8 alkyl; R4 and R5 are each independently fluorine atom or chlorine atom; R6 is C1 - C3 alkyl or C1 - C3 alkyloxy; and carbon atom with "*" attached to it is an asymmetric carbon, its pharmaceutically acceptable salt, or solvate thereof. <EOS>